Publication

Publication

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

  • AUTHORS Duska, et al
  • Programs OPN-2853
https://ascopubs.org/doi/abs/10.1200/PO.23.00235
Publication

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

https://doi.org/10.1016/j.leukres.2022.106884
Publication

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

https://doi.org/10.3389/fonc.2021.760789
Publication

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia

https://doi.org/10.3324/haematol.2020.247346
Publication

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

https://doi.org/10.1182/bloodadvances.2020002231
Publication

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

https://doi.org/10.1038/s41416-019-0724-y
Publication

PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma

https://doi.org/10.1111/pcmr.12845
Publication

Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer

https://doi.org/10.1530/ERC-19-0107
Publication

The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner

https://doi.org/10.1111/pcmr.12788
Publication

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma

  • AUTHORS Ambrosini, et al
  • Programs OPN-51107
https://doi.org/10.1158/0008-5472.CAN-18-3177